Study Evaluates Total Neoadjuvant Therapy for Rectal Cancer

Introduction to Rectal Cancer

A recent study in the United States assessed whether total neoadjuvant therapy enhances the effectiveness of rectal cancer treatment. According to the American Cancer Society, over 43,000 individuals in the U.S. were diagnosed with rectal cancer in 2018. This form of cancer develops from the lining of the rectum, which constitutes the final few inches of the large intestine. Common symptoms include alterations in bowel habits, diarrhea, bowel obstruction, and bleeding. Although the precise cause of rectal cancer remains unclear, several risk factors have been identified, including aging, smoking, and a high-fat diet.

Treatment Approaches for Rectal Cancer

The management of rectal cancer is contingent upon the disease’s stage. Surgery serves as the primary treatment across all stages. For stage II and III locally advanced rectal cancer, the standard clinical approach typically involves preoperative chemoradiotherapy (chemoRT), followed by total mesorectal excision and postoperative adjuvant chemoradiotherapy. This method has proven effective in reducing the incidence of distant recurrence, though it does not significantly impact local recurrence rates.

Overview of the Study

In a recent publication in JAMA Oncology, researchers conducted a study to evaluate the efficacy of total neoadjuvant therapy in treating late-stage rectal cancer. Unlike the conventional protocol of administering chemoRT followed by postoperative adjuvant chemotherapy, total neoadjuvant therapy involves the delivery of both chemoradiation and chemotherapy prior to surgery.

Study Participants and Methodology

The study encompassed 811 patients diagnosed with stages III, IV, or node-positive rectal cancer. Of these, 320 received the traditional chemoRT combined with planned adjuvant chemotherapy, while 308 were treated with the new total neoadjuvant therapy approach. Participants were recruited between 2009 and 2015 from the Memorial Sloan Kettering Cancer Center in the United States. This research represents the largest published series of patients with rectal cancer treated using total neoadjuvant therapy.

Findings and Outcomes

The researchers analyzed treatment and outcome data from both patient groups, focusing on chemotherapy tolerance, tumor response, and short-term oncological outcomes. The results indicated that total neoadjuvant therapy facilitated the delivery of planned systemic therapy, achieving a 15% higher success rate compared to the traditional method. Additionally, patients undergoing total neoadjuvant therapy exhibited increased rates of pathological and sustained clinical responses within 15 weeks post-surgery.

Conclusion and Future Directions

Total neoadjuvant therapy demonstrates short-term advantages over the traditional chemoRT and adjuvant chemotherapy regimen for locally advanced rectal cancer. However, further longitudinal studies are necessary to thoroughly evaluate its effectiveness on overall survival rates.

Reference

Cercek A., Roxburgh C.S., Strombom P., et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology. Published online March 22, 2018. DOI 10.1001/jamaoncol.2018.0071.